Background: No data have been so far reported on the relationship between polymorphisms of LEP gene and cardiovascular disease. Patients and methods: We genotyped a tetranucleotide repeat mapped in the 3 0 UTR of the LEP gene (LEP-tet) in 109 subjects with cardiovascular events and in 109 control subjects. Results: Univariate analysis and multivariate logistic regression analysis adjusted for age, gender, smoking status, history of hyperlipidemia, hypertension or diabetes showed not significant association between the genotype of the LEP-tet and cardiovascular diseases. Moreover, no differences were observed in the plasma leptin concentrations between cases and control subjects (22719 vs 22714 ng/ml, P ¼ 0.52) and in relation to the LEP-tet classes or carriage of specific allelels (P ¼ 0.76 for the association between LEP-tet classes and leptin levels in overall analysis). Conclusions: In conclusion, our data do not support an association between the LEP-tet microsatellite polymorphism of the human LEP gene and cardiovascular diseases.
Introduction
Leptin is an adipocyte-derived hormone that regulates food intake and energy expenditure. 1 Mutations in the leptin gene cause severe obesity in animal models, and the human leptin gene LEP (alias OB, 7q31. 3, OMIM #164160) has been found mutated in very rare forms of human obesity. 2, 3 The identification of a polymorphic tetranucleotide repeat in the 3 0 flanking region of the LEP gene (LEP-tet) provided an useful marker for linkage and association studies between this gene and a number of phenotypes other that obesity, such as noninsulin-dependent diabetes mellitus, hypertension and insulin resistance syndrome. 4, 5 LEP-tet is composed by 15 alleles, which can be divided into two groups with different size distribution: a shorter one (class I) and a longer one (class II). 4 Previous studies showed a significant association between LEP Class I alleles and hypertension, but no significant differences in body mass index (BMI) and insulin sensitivity were observed in patients with different genotypes. 5 In contrast, a sib pair linkage analysis did not show any evidence of linkage between the LEP gene and hypertension in African Americans. 6 A study based on sib ship data from Mexican American families found that quantitative variations in obesity-related trait and insulin precursors were linked to the LEP gene region; 7 however, other studies showed no significant difference in the frequency of LEP alleles between noninsulin-dependent diabetic patients and controls. 4 Thus, contrasting results have been found about the association between LEP polymorphisms and traditional cardiovascular risk factors. So far, no studies have focused on the relationship between LEP polymorphisms and cardiovascular events. Interestingly, a predictive role of leptin plasma levels for the risk of cardiovascular disease even after adjustment for classic risk factors has been recently showed. 8 Accordingly, a strong association between leptin plasma levels and increased risk of myocardial infarction and stroke has been reported. 9, 10 In the present study, we examined the Class I/Class II and the individual allele genotypes of the LEP-tet in patients screened for cardiovascular risk, to evaluate the role of this polymorphism as a marker for cardiovascular diseases. In addition, since previous studies had suggested an association between marker D7S530, mapped in the vicinity of the LEP gene, with serum leptin levels, 11 we also tested circulating leptin levels in our study population.
Material and methods
In total, 300 outpatients over 40 years referred to our Department of Internal Medicine, for a cardiovascular risk program, between December 2001 and may 2002 were consecutively included into the study. A total of 109 patients, with a history of ischemic stroke (n ¼ 31), myocardial infarction (n ¼ 67) or both (n ¼ 11) were enlisted in the group of patients with cardiovascular diseases (CVD). Among the remaining 191 subjects without CVD, we selected 109 control subjects frequency matched by age (5 year categories) and gender with cases. All subjects were Caucasian from central and southern Italy and belonged to independent pedigrees. Hospital records for all reported cases of CVD were requested.
Patients with a history of ischemic stroke were selected after clinical evaluation, and abnormal findings depicted by brain computed tomography or magnetic resonance imaging. 12 The diagnosis of myocardial infarction was based on the combination of cardiac signs and symptoms, electrocardiographic findings and biomarkers (i.e creatine kinase MB isoenzyme and troponin elevation). 13 Body mass index 14 Hyperlipidemia was defined as cholesterol level 45.2 mmol/l and triglycerides 41.7 mmol/l 15 or use of cholesterol-lowering medication. Hypertension was defined as a history of systolic blood pressure X140 mmHg, diastolic pressure X90 mmHg, or use of antihypertensive therapy. Plasma concentration of leptin was measured in duplicate using a commercial ELISA kit (Alexis Corporation), according to the recommendations by the manufacturer. All patients gave informed consent for the study, which was approved by the local ethics committee.
Genotyping of leptin gene polymorphism
The region of the LEP gene containing the tetranucleotide repeat was PCR amplified according to Shintani et al. 4 For the characterization of the Class I or Class II alleles, PCR products were run in 2% agarose gel. For the identification of each allele, PCR reactions were carried out using a 6-FAM labeled fluorescent primer (5 0 AGT TCA AAT AGA GGT CCA AAT CA) and products were run on an ABI PRISM 310 Genetic Analyzer. 310 GeneScan 2.1 software was used for genotyping. Alleles were classified according to Shintani et al. 
Results
The main clinical features of the subjects included in the study are depicted in Table 1 . Genotype Distribution in patients and controls and risk of CVD for the LEP-tet polymorphism are shown in Table 2 . Genotype distribution was in Hardy-Weinberg equilibrium, both in cases and in control subjects (w 2 ¼ 0.01, df ¼ 1, P ¼ 0.93 and w 2 ¼ 0.54, df ¼ 1, P ¼ 0.46, respectively), and was not significantly different between cases and control subjects (w 2 ¼ 0.25, df ¼ 2, P ¼ 0.88). The frequencies of the class I and class II alleles in the control group was 0.29 and 0.71, respectively, equal to the one in patients with CVD (w 2 ¼ 0.04, P ¼ 0.83).
The distribution of the individual LEP-tet alleles in cases and control subjects is shown in Table 3 . Although the prevalence of some specific allele (i.e. allele II-4) was slightly different between cases and control subjects, this difference was not significant. The analysis of the association between LEP-tet polymorphism and hypertension showed that in the control group, the frequency of the class I alleles was 0.30 in hypertensive and 0.28 in normotensive patients (P ¼ 0.70); in cases the frequency of the class I alleles was 0.28 in hypertensive and 0.29 in normotensive patients (P ¼ 0.93).
No evidence was detected for an association between of the LEP gene marker and BMI, both in cases and control subjects (data not shown).
Plasma leptin concentration was measured in 89 control subjects and 92 cases. Female subjects had higher leptin levels than male subjects (30721 vs 15714 pg/ml, Po0.001 in controls and 30714 vs 16711 pg/ml, Po0.001 in cases). Leptin levels were higher in diabetic patients than in nondiabetic patients (30725 vs 21718, P ¼ 0.15 in controls and 25713 vs 21714, P ¼ 0.21 in cases) but the differences were not statistically significant. Cases and control subjects had similar distribution of leptin levels, (22719 and 22714, respectively; P ¼ 0.27).
Leptin levels positively correlated with BMI levels, both in cases (Pearson correlation coefficient (R) ¼ 0.33, P ¼ 0.028 in males and R ¼ 0.36, P ¼ 0.022 in females) and in controls (R ¼ 0.52, P ¼ 0.0002 in males and R ¼ 0.37, P ¼ 0.016 in females).
No differences were observed in the levels of plasma leptin according to LEP-tet classes (P ¼ 0.76 for the association between LEP-tet classes and leptin in overall analysis; P ¼ 0.86 in males; P ¼ 0.35 in females; P ¼ 0.47 in cases; P ¼ 0.54 in controls; P ¼ 0.40 in nondiabetic patients; P ¼ 0.78 in diabetic patients). In multiple regression analysis with gender, case status, BMI and LEP-tet classes as covariates, leptin levels were associated with gender (Po0.0001, partial R 2 ¼ 0.23) and BMI (Po0.0001, partial 
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Multivariate logistic regression analysis of the risk of CVD associated with variants of the LEP-tet gene remained unaltered after the inclusion of leptin levels in the model, or after stratification for only stroke or only myocardial infarction (data not shown).
Discussion
In the present study, we genotyped a tetranucleotide repeat mapped in the 3 0 UTR of the LEP gene in 109 subjects with cardiovascular diseases (i.e. previous myocardial infarction or stroke) and in 109 controls matched for age and gender in order to verify an association between different LEP genotypes and cardiovascular disease. Our results showed that both the distribution of the genotypes in the Class I and Class II (I/I, I/II and II/II) and the frequency of individual alleles were not associated with CVD. In fact, although some individual allele of the LEP-tet showed a different frequency in cases and in control subjects, this association was neither statistically significant nor independent from other cardiovascular risk factors in logistic regression analysis.
Two recent studies based on genetic association analysis using the same LEP-tet marker suggested an association between genotype I/I and class I alleles with obesity in noninsulin-dependent diabetes mellitus 4 and between genotype I/I and hypertension. 5 However, in this setting, coronary artery or cerebrovascular diseases were not considered 4 or were absent in the patients studied 5 Thus, our study extend these previous observations analysing the LEPtet polymorphism in patients with previous cardiovascular diseases. In contrast with reported association between LEPtet and other risk factors for CVD, 4,5 no evidence was found in the present study for an association of the LEP-tet gene markers to BMI and hypertension both in cases and in control subjects. Indeed several studies, do not rule out a role of the LEP gene in the risk for cardiovascular diseases. In fact, Li et al. 17 found recently that a region of 7q31.1 (close to the LEP locus on 7q31.3) was most consistent linked to human obesity. Jiang et al. 18 found that five SNPs positioned beyond the defined promoter region of the LEP gene showed strong association with human obesity and was transmitted to obese offspring. A recent study 19 demonstrated a strong association between a rare polymorphism in the 3 0 untranslated region of LEP and pulse pressure and carotid intimamedial thickness; the effects were not related to BMI or plasma leptin levels. Thus, differences in subject's enrolment and the presence of other variants within the LEP gene (different from the LEP-tet) should be considered to explain the relationship between LEP gene and cardiovascular risk factors.
Our findings showed that plasma leptin concentration was not significantly different between subjects with and without cardiovascular diseases. Our finding disagree with other studies, 20 which found that hypertensive patients with myocardial infarction had higher plasma leptin levels than control subjects. In our study, 66% of control subjects and 71% of cases were hypertensive subjects and cardiovascular disease was defined as history of myocardial infarction or stroke. Thus, both the characteristic of tested subjects and the sample size could explain this discrepancy. We did not find any significant correlation between plasma leptin concentrations and LEP-tet genotype. These data are in line with a previous study which showed no association between the LEP-tet polymorphism and circulating leptin levels in hypertensive subjects. 5 Thus, our study do not support a functional role played by different alleles of the LEP-tet polymorphism, both of Class I and Class II, in determining the leptin plasma levels.
In conclusion, our data do not support an association between the LEP-tet microsatellite polymorphism of the human LEP gene and cardiovascular diseases. In addition, in our study, LEP-tet polymorphism does not appear to exert any effect through actions on plasma leptin level, BMI or hypertension. The leptin gene region of the chromosome 7q remains an attractive target for further studies on linkage and linkage disequilibrium genetic mapping and the onset cardiovascular diseases.
